Leah Miller
Family · Goshen, INNPI 1891807368
Payments from drug & device makers
Across 149 payments — averaging $38.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Livanova USA, Inc.$938
- Biohaven Pharmaceuticals, Inc.$392
- Catalyst Pharmaceuticals, Inc.$284
- Axsome Therapeutics, Inc.$187
- SK Life Science, Inc.$182
- plus $2K from 29 others
What the payments were for
- Travel & lodging$2925%
- Food & beverage$5,44395%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 58 | $1,392 |
| Livanova USA, Inc. | 5 | $938 |
| Biohaven Pharmaceuticals, Inc. | 5 | $392 |
| Catalyst Pharmaceuticals, Inc. | 11 | $284 |
| Axsome Therapeutics, Inc. | 3 | $187 |
| SK Life Science, Inc. | 6 | $182 |
| UCB, Inc. | 3 | $182 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $177 |
| Acadia Pharmaceuticals Inc | 5 | $176 |
| EMD Serono, Inc. | 5 | $174 |
| Lundbeck LLC | 3 | $169 |
| Otsuka America Pharmaceutical, Inc. | 3 | $166 |
| Eisai Inc. | 3 | $152 |
| Neurelis, Inc. | 2 | $147 |
| Idorsia Pharmaceuticals US Inc | 1 | $125 |
| Pfizer | 7 | $109 |
| Novartis | 2 | $98 |
| Lilly USA, LLC | 3 | $85 |
| Si-bone, Inc. | 1 | $83 |
| TG Therapeutics, Inc. | 3 | $68 |
| Jazz Pharmaceuticals Inc. | 2 | $67 |
| Medtronic | 2 | $56 |
| Biogen | 2 | $52 |
| Teva Pharmaceuticals USA, Inc. | 1 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| Argenx US, Inc. | 1 | $27 |
| Amneal Pharmaceuticals LLC | 1 | $23 |
| Cala Health, Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $22 |
| Acorda Therapeutics, Inc | 1 | $20 |
| AstraZeneca | 1 | $20 |
| CSL Behring | 1 | $18 |
| Cycle Pharmaceuticals Inc | 1 | $18 |
| Novo Nordisk | 1 | $17 |
| Upsher-smith Laboratories LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,737 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 70 | $104,901 |
| UbrelvyUbrogepant | 47 | $73,515 |
| Aimovig AutoinjectorErenumab-Aooe | 63 | $52,931 |
| Emgality PenGalcanezumab-Gnlm | 50 | $39,903 |
| VimpatLacosamide | 22 | $24,836 |
| BriviactBrivaracetam | 15 | $23,895 |
| AptiomEslicarbazepine Acetate | 17 | $21,890 |
| Topiramate ErTopiramate | 13 | $18,668 |
| ReyvowLasmiditan Succinate | 18 | $15,203 |
| Levetiracetam | 114 | $5,975 |
| Lacosamide | 32 | $5,043 |
| Sumatriptan Succinate | 38 | $4,124 |
| Primidone | 85 | $3,075 |
| Gabapentin | 165 | $3,034 |
| Carbamazepine | 37 | $2,918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt, Dilantin | $109 | $107,00484 claims |
| AbbVieUbrelvy | $1,392 | $73,51547 claims |
| UCB, Inc.Vimpat, Briviact | $182 | $48,73137 claims |
| Lilly USA, LLCReyvow | $85 | $15,20318 claims |
| Upsher-smith Laboratories LLCTopiramate | $15 | $1,280109 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.
Other family in Goshen
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.